Guinea-Bissau Suspends Controversial Vaccine Study Amid Ethical Concerns and RFK Jr. Policy Shift
Table of Contents
A U.S.-funded study investigating the timing of hepatitis B vaccinations for infants in Guinea-Bissau has been suspended following widespread criticism from public health experts and a recent policy change initiated by Health Secretary Robert F. Kennedy jr. The $1.6 million research project, approved by the Centers for Disease Control and Prevention (CDC) last month, aimed to compare the efficacy of administering the vaccine at birth versus six weeks of age – a deviation from globally accepted standards of care.
The suspension, announced on Thursday by Guinea-Bissau’s Public Health Minister quinhin Nantote, comes after mounting concerns that the study violated key ethical principles and perhaps put vulnerable infants at risk. The controversy also highlights a broader debate over vaccine policy, fueled by Mr. Kennedy’s recent decision to reverse the CDC’s longstanding recommendation for universal infant vaccination.
Ethical outcry and Questionable research Practices
The study, conducted by researchers at the University of Southern Denmark, quickly drew fire from the public health community. Critics argued that withholding the birth-dose vaccine – recommended by the World health Organization (WHO) – from half of the 14,000 participating infants was unethical,particularly given the high prevalence of hepatitis B in Guinea-Bissau. One in five peopel in the West African nation carries the virus,which can led to severe liver damage and cancer.
“This brings us back to poor research practices, arguing that the standard of care cannot be met in a given setting,” explained Dr. Boghuma Titanji, an infectious disease physician at Emory University. “Researchers are taking advantage of a situation of scarcity to conduct this unethical study.”
The core of the ethical debate centers on the principle of providing the best available care to all participants in a clinical trial. International protocols mandate that study participants receive globally accepted standards of care. In this case, that standard is the birth-dose hepatitis B vaccine, which prevents mother-to-child transmission of the virus and considerably reduces the risk of chronic liver disease. The study’s design, though, deliberately delayed vaccination for half of the infants, raising concerns about unneeded risk.
Moreover, researchers did not plan to screen pregnant women for hepatitis B, a crucial step to identify mothers who require immediate intervention to protect their newborns.
Policy Shift and Funding Cuts
The timing of the study’s approval coincided with a significant policy shift in the United States. Days before the CDC grant was finalized, Mr. Kennedy reversed the agency’s recommendation for universal infant hepatitis B vaccination, citing the need for further research. He specifically referenced the work of the Danish research team as justification for his decision,despite their findings demonstrating both benefits and harms of the vaccine.
This decision was compounded by Mr. Kennedy’s decision to end U.S. funding for GAVI, the international organization that supports vaccine programs in low-income countries, severely constraining its finances. Congress is currently considering a spending bill that would restore funding to GAVI.
Questions of Approval and Transparency
The legitimacy of the study’s ethical approval process is also under scrutiny. While the Danish researchers claimed the study was approved by relevant authorities in Guinea-Bissau, Health Minister Nantote expressed uncertainty about whether a proper review had taken place.
“We have no evidence that they held any meetings, we don’t even have minutes of the meetings that where negotiated and approved,” Nantote stated at a press conference. “We think they didn’t hold a meeting, they didn’t come together and they didn’t address the issue.”
An unnamed official at Guinea-Bissau’s National Health Research Ethics Committee initially told The New York Times that the study was approved in the fourth quarter of 2025, prior to a recent coup and subsequent political instability. However, Nantote’s statements cast doubt on this claim.
A Nation’s Limited Resources and the Burden of Disease
Guinea-Bissau, consistently ranked among the world’s least developed countries, faces significant challenges in providing adequate healthcare. The country lacks essential medical infrastructure, including oncologists and MRI machines.The logistical hurdles of delivering vaccines, particularly the birth-dose, are also substantial, with roughly half of births occurring at home.
“The reason why children in Guinea-Bissau are currently not receiving a birth dose is not because of uncertainty about the vaccine. It’s because they are unable to implement the policy for resource-related reasons,” explained Dr. Keymanthri Moodley, emeritus professor of bioethics at the University of Stellenbosch in South Africa.
The study’s design, critics argue, exploited these vulnerabilities, attempting to leverage the country’s limited resources to conduct research that would be considered unethical in settings with more robust healthcare systems.
Past Controversies and Evolving Ethical Standards
This is not the first time the Danish research team, led by Christine Stabell Benn, has faced ethical criticism. A previous trial conducted by the team involved administering a placebo to women, resulting in infant infections.The researchers defended the trial by arguing that the drug was unavailable in the study locations, but the incident led to changes in the Declaration of Helsinki, an international agreement governing medical research ethics, requiring control groups to receive the moast effective intervention.
health officials in Guinea-Bissau also expressed frustration with the lack of communication surrounding the study.”There is a huge lack of information about this health test or any health experiment,” said Cadija Mané, a former senior official at the health ministry. “There is a need for better information flow.”
The suspension of the study in Guinea-Bissau underscores the critical importance of ethical oversight in global health research and the need to prioritize the well-being of vulnerable populations. It also raises basic questions about the responsibility of researchers and policymakers to ensure that scientific inquiry does not come at the expense of human dignity and health.
Related reading
